Sunshine Biopharma Files 8-K on Shareholder Vote

TL;DR

Sunshine Biopharma had a shareholder vote on Dec 11, 2025. Details in 8-K.

AI Summary

Sunshine Biopharma Inc. filed an 8-K on December 12, 2025, reporting on a matter submitted to a vote of security holders on December 11, 2025. The company, incorporated in Colorado with its principal executive offices in Fort Lauderdale, FL, is in the pharmaceutical preparations industry.

Why It Matters

This filing indicates a significant event involving shareholder decisions, which could impact the company's governance and future strategic direction.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting a shareholder vote, with no immediate financial distress or significant negative events indicated.

Key Numbers

• 001-41282 — Commission File Number (Identifies the company's SEC filing history)
• 20-5566275 — IRS Employer Identification Number (Tax identification for the company)

Key Players & Entities

• Sunshine Biopharma Inc. (company) — Registrant
• December 11, 2025 (date) — Date of earliest event reported
• December 12, 2025 (date) — Filing date
• Colorado (jurisdiction) — State of incorporation
• Fort Lauderdale, FL (location) — Business address

FAQ

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC

Filing Documents

• sunshine_8k.htm (8-K) — 32KB
• 0001683168-25-009103.txt ( ) — 236KB
• sbfm-20251211.xsd (EX-101.SCH) — 3KB
• sbfm-20251211_def.xml (EX-101.DEF) — 26KB
• sbfm-20251211_lab.xml (EX-101.LAB) — 36KB
• sbfm-20251211_pre.xml (EX-101.PRE) — 25KB
• sunshine_8k_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of

Item 5.07 Submission of Matters to a Vote of Security Holders. On December 11, 2025, Sunshine Biopharma Inc. (the "Company") held its annual meeting of stockholders. At the meeting, (i) Dr. Steve N. Slilaty, Mr. Camille Sebaaly, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller were each elected as directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified, (ii) stockholders ratified the board of directors' appointment of M&K CPAS, PLLC as the Company's independent registered public accounting firm for 2025, and (iii) stockholders approved an amendment to the Company's 2023 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder to 683,000. The vote on these matters was as follows: (i) Election of Directors: FOR WITHHELD BROKER NON-VOTE Dr. Steve N. Slilaty 130,382,043 58,298 1,774,854 Mr. Camille Sebaaly 130,382,204 58,137 1,774,854 Dr. Rabi Kiderchah 130,383,638 56,703 1,774,854 Mr. David Natan 130,382,135 58,206 1,774,854 Dr. Andrew Keller 130,383,893 56,448 1,774,854 (ii) Ratification of the board of directors' appointment of M&K CPAS, PLLC as the Company's independent registered public accounting firm for 2025. FOR AGAINST ABSTAIN BROKER NON-VOTE 132,026,819 177,963 10,413 0 (iii) Approval of an amendment to the Company's 2023 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder to 683,000. FOR AGAINST ABSTAIN BROKER NON-VOTE 130,139,733 293,771 6,837 1,774,854 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 12, 2025 SUNSHINE BIOPHARMA INC. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR